CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017--
WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company
focused on developing targeted therapies for patients impacted by rare
diseases, today announced that Paul Bolno, M.D., MBA, President and
Chief Executive Officer, will be presenting at the following upcoming
Leerink Partners Global Healthcare Conference 2017
February 15th at 1:30 P.M. ET – New York
RBC Capital Markets 2017 Healthcare Conference
23rd at 2:05 P.M. ET – New York
A live webcast of each presentation will also be available on the
investor relations page of the WAVE Life Sciences corporate website at http://ir.wavelifesciences.com.
After each webcast, a replay will remain archived on the corporate
website for a limited time.
About WAVE Life Sciences
At WAVE Life Sciences, we are driven by an unwavering passion and
commitment to deliver on our mission of confronting challenging diseases
by developing transformational therapies and empowering patients. We are
utilizing our innovative and proprietary synthetic chemistry drug
development platform to design, develop and commercialize rationally
redesigned nucleic acid therapeutics that precisely target the
underlying cause of rare and other serious genetically defined diseases.
Given the versatility of our chemistry platform, WAVE’s deep, diverse
pipeline spans multiple modalities including antisense, exon-skipping,
and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005286/en/
Source: WAVE Life Sciences Ltd.
Media and Investors:
WAVE Life Sciences
Gregory Kelley, 404-836-2302